Rein Therapeutics (RNTX) News
NASDAQ: RNTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RNTX news summary
We found 2 recent headlines mentioning Rein Therapeutics (RNTX): 2 in the past week and 2 in the past 30 days, most often from Nasdaq, GlobeNewswire. RNTX is making an outsized move today, down 8.38% at $0.3369, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Rein Therapeutics Announces Preliminary Blinded Phase 2 RENEW Data and Reports Third Quarter 2026 Financial Results", was published by Nasdaq on Nov 16, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Rein Therapeutics headlines
- Rein Therapeutics Announces Preliminary Blinded Phase 2 RENEW Data and Reports Third Quarter 2026 Financial ResultsRein Therapeutics Inc. announced preliminary blinded twelve-week observations from its ongoing Phase 2 RENEW clinical trial evaluating its lead drug candidate, LTI-03, in patients with idiopathic…Nasdaq
- Rein Therapeutics Announces Preliminary Blinded Phase 2 RENEW Data Showing Encouraging Lung Function Trends in Patients with Idiopathic Pulmonary Fibrosis and Reports Third Quarter 2026 Financial ResultsAUSTIN, Texas, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and…GlobeNewswire